What is the best management approach for recurrent endometrial polyps in a woman trying to conceive, given a history of multiple polyp removals?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Recurrent Endometrial Polyps in Women Trying to Conceive

For recurrent endometrial polyps in a woman attempting pregnancy, proceed with hysteroscopic polypectomy followed by 6 months of progestin therapy (preferably levonorgestrel-releasing intrauterine device) to prevent recurrence, then actively pursue conception through assisted reproductive technologies if needed.

Immediate Surgical Management

  • Hysteroscopic polypectomy is the definitive treatment for your recurrent polyps, as blind dilatation and curettage should be avoided for polyp removal 1, 2
  • Office hysteroscopy with "see and treat" approach is feasible, safe, and can often be performed without anesthesia 1, 2
  • Complete polyp removal under hysteroscopic guidance is the recommended surgical treatment, as it allows both visualization and effective resection 3, 2

Post-Polypectomy Prevention Strategy

The critical step after polyp removal is preventing recurrence before you conceive:

  • Levonorgestrel-releasing intrauterine device (LNG-IUS) is the preferred method for preventing polyp recurrence, as it provides higher regression rates, lower recurrence rates, and fewer adverse events compared to oral progestins 4, 5
  • Maintenance progestin treatment for at least 6 months provides optimal endometrial protection 4
  • Alternative oral progestins include medroxyprogesterone acetate (400-600 mg/day) or megestrol acetate (160-320 mg/day) if LNG-IUS cannot be used 4, 6

Monitoring During Prevention Phase

  • Perform endometrial sampling (biopsy or D&C) every 3-6 months during progestin treatment to ensure no pathological changes 4, 6
  • Continue treatment until no pathological changes are detected in two consecutive endometrial biopsies 5
  • After the 6-month treatment period, continue regular follow-up every 6 months to monitor for late recurrence 4

Fertility Considerations

Once polyp recurrence prevention is complete, actively pursue pregnancy:

  • Women with unexplained infertility may benefit from endometrial polypectomy for future natural pregnancy 7
  • Patients who achieve disease remission should be advised to seek assistance through assisted reproductive technologies to optimize conception timing 5
  • Consultation with a fertility specialist is recommended prior to and after completing the prevention therapy 8

Important Contraindications to Progestin Therapy

Use progestin cautiously or avoid if you have: 4, 6

  • History of breast cancer
  • Stroke or myocardial infarction
  • Pulmonary embolism or deep vein thrombosis
  • Active smoking

Why This Approach Matters

The recurrence rate after polypectomy alone is significant, and approximately 25% of polyps may resolve spontaneously, but your history of multiple recurrences indicates you need active prevention 3. The 6-month progestin window provides endometrial protection while minimizing delay in your fertility goals. Pregnancy itself will provide additional protective benefit through high progesterone levels, though it does not eradicate lesions completely 9.

References

Research

Removal of uterine polyps: clinical management and surgical approach.

Climacteric : the journal of the International Menopause Society, 2020

Research

Endometrial polyps: diagnosis and treatment options - a review of literature.

Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy, 2021

Research

To treat or not to treat? An evidence-based practice guide for the management of endometrial polyps.

Climacteric : the journal of the International Menopause Society, 2020

Guideline

Dydrogesterone for Endometrial Polyp Recurrence Prevention

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Chinese guidelines on the management of endometrial hyperplasia.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2024

Guideline

Management of Endometrial Hyperplasia without Atypia Resistant to Oral Progestin

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Management of endometrial polyps in infertile women: A mini-review.

Clinical and experimental reproductive medicine, 2021

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Endometriotic Activity During Pregnancy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.